TOPAS Fecal Incontinence Device Gets Unanimous Support For Approval At FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
All members of the agency's Gastroenterology and Urology Devices Panel were convinced by Astora Women’s Health's evidence in support of PMA approval for the TOPAS mesh implant device for fecal incontinence.
You may also be interested in...
Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel
Endo International plans to shutter its Astora Women's Health business unit – formerly part of American Medical Systems – this month due to ongoing legal concerns tied to the company’s vaginal mesh products. What’s unclear is what this means for the company’s investigational fecal incontinence treatment, which received unanimous support from an FDA advisory panel just days before the shutdown was announced.
Surgeons Slowed Use of Pelvic Mesh Following FDA Warning, N.Y. Study Shows
Use of surgical mesh for pelvic organ prolapse procedures in New York state declined following a 2011 FDA warning, according to a new study.
CDRH Prioritizes Leveraging Real-World And Patient-Preference Data, Enhancing Quality
In its 2016-2017 strategic priorities, the device center lays out specific goals for putting more emphasis on real-world postmarket data to support regulatory decisions, making better use of patient-preference input, and enhancing quality at CDRH and in industry. Topping FDA's list: gaining access to 25 million electronic patient records with device identification from global registries, insurance claims data and electronic health records, and expanding that number to 100 million by the end of 2017 to support premarket and postmarket decisions.